Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Cyclerion Therapeutics, Inc.
Cyclerion’s sGC Stimulator Portfolio Generates Revenues to Enable Company Growth
December 17, 2024
From
Cyclerion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CYCN
Regina Graul, Ph.D., Promoted to Chief Executive Officer
August 07, 2024
From
Cyclerion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CYCN
Cyclerion Appoints Regina Graul, Ph.D., as President
December 04, 2023
From
Cyclerion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CYCN
Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator
November 30, 2023
From
Cyclerion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CYCN
Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets
July 31, 2023
From
Cyclerion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CYCN
Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement
June 01, 2023
From
Cyclerion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CYCN
Cyclerion Announces Reverse Stock Split
May 15, 2023
From
Cyclerion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CYCN
Cyclerion Announces Corporate Updates and Q1 2023 Financial Results
May 11, 2023
From
Cyclerion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CYCN
Cyclerion Announces Definitive Agreement for Zagociguat and CY3018
May 11, 2023
From
Cyclerion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CYCN
Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement
April 03, 2023
From
Cyclerion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CYCN
Cyclerion Therapeutics Receives U.S. FDA Orphan Drug Designation for Zagociguat for the Treatment of Mitochondrial Diseases
March 27, 2023
From
Cyclerion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CYCN
Cyclerion Reports Corporate Update and Full Year 2022 Financial Results
March 22, 2023
From
Cyclerion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CYCN
Cyclerion Concludes Unsolicited Proposal Is Not in The Best Interest of The Company
November 22, 2022
From
Cyclerion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CYCN
Cyclerion Announces Mitochondrial Disease-Focused Corporate Strategy
October 06, 2022
From
Cyclerion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CYCN
Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia (CIAS)
July 28, 2022
From
Cyclerion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CYCN
Steven E. Hyman, M.D., Appointed to Cyclerion Therapeutics’ Board of Directors
July 26, 2022
From
Cyclerion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CYCN
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.